Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) is scheduled to be posting its quarterly earnings results after the market closes on Wednesday, November 6th. Analysts expect Trevi Therapeutics to post earnings of ($0.12) per share for the quarter.
Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.01). During the same quarter in the previous year, the company earned ($0.07) EPS. On average, analysts expect Trevi Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Trevi Therapeutics Price Performance
Trevi Therapeutics stock traded down $0.05 during trading hours on Thursday, hitting $3.01. The company had a trading volume of 141,476 shares, compared to its average volume of 280,389. The firm has a market cap of $218.50 million, a PE ratio of -7.85 and a beta of 0.97. Trevi Therapeutics has a one year low of $0.97 and a one year high of $4.00. The firm has a 50-day moving average of $3.14 and a 200 day moving average of $2.90.
Analyst Upgrades and Downgrades
TRVI has been the topic of several research analyst reports. Needham & Company LLC reissued a "buy" rating and issued a $8.00 price target on shares of Trevi Therapeutics in a report on Friday, October 4th. Raymond James started coverage on shares of Trevi Therapeutics in a report on Friday, August 30th. They issued an "outperform" rating and a $9.00 price target on the stock. HC Wainwright reaffirmed a "buy" rating and set a $6.00 target price on shares of Trevi Therapeutics in a report on Tuesday, October 22nd. EF Hutton Acquisition Co. I raised shares of Trevi Therapeutics to a "strong-buy" rating in a report on Monday, August 19th. Finally, Leerink Partnrs raised shares of Trevi Therapeutics to a "strong-buy" rating in a report on Monday, September 9th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Trevi Therapeutics currently has an average rating of "Buy" and an average price target of $7.43.
Read Our Latest Analysis on TRVI
Insider Buying and Selling
In related news, insider Thomas Sciascia sold 18,660 shares of Trevi Therapeutics stock in a transaction on Friday, August 16th. The shares were sold at an average price of $2.76, for a total transaction of $51,501.60. Following the completion of the transaction, the insider now owns 220,315 shares of the company's stock, valued at $608,069.40. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Thomas Sciascia sold 18,660 shares of Trevi Therapeutics stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $2.76, for a total transaction of $51,501.60. Following the completion of the transaction, the insider now directly owns 220,315 shares in the company, valued at $608,069.40. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jennifer L. Good sold 10,981 shares of Trevi Therapeutics stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $3.02, for a total transaction of $33,162.62. Following the transaction, the chief executive officer now owns 213,313 shares of the company's stock, valued at $644,205.26. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 40,355 shares of company stock worth $116,663. Corporate insiders own 24.37% of the company's stock.
About Trevi Therapeutics
(
Get Free Report)
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.
Further Reading
Before you consider Trevi Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trevi Therapeutics wasn't on the list.
While Trevi Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
